Egalet announced the launch of Oxaydo (oxycodone HCI) tablets, the first immediate-release oxycodone formulation to deter abuse via snorting.

Oxycodone HCl is a CII controlled substance and a pure opioid agonist. It is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses. Its principal therapeutic action is analgesia and is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

RELATED: FDA Committees to Discuss Potential Dosing Error for New Oxycodone IR Formulation

Oxaydo tablets contain an inactive ingredient that may cause nasal burning if the drug is manipulated. A double-blind crossover study found that six times more recreational users reported that they would not take Oxaydo again compared to subjects exposed to immediate-release oxycodone.

Oxaydo tablets are available in 5mg and 7.5mg strength tablets in 100-count bottles.

For more information call (855) 228-7201 or visit